Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Gabrielli

Showing results (21-30 of 288) with videos related to

Pageof 29
Sort By:
Giornale Italiano Di Cardiologia (2006)|February 28, 2023
[Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease]Manuela Benvenuto, Gaetano Panzarella, Ermal Shehaj, et al.
Frontiers in Cardiovascular Medicine|September 18, 2025
Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)Giovanna Geraci, Carmine Riccio, Fabrizio Oliva, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|August 30, 2021
ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetesEdoardo Gronda, Claudio Napoli, Massimo Iacoviello, et al.
Giornale Italiano Di Cardiologia (2006)|December 27, 2022
[ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure]Stefania Angela Di Fusco, Antonella Spinelli, Stefano Aquilani, et al.
Giornale Italiano Di Cardiologia (2006)|November 27, 2023
[ANMCO Scientific statement: Differences and similarities between direct oral anticoagulants - 10 years of scientific evidence and clinical practice]Stefania Angela Di Fusco, Pietro Scicchitano, Massimo Grimaldi, et al.
Giornale Italiano Di Cardiologia (2006)|June 19, 2018
[Decision-making issues in the clinical management of pericarditis. A statement of the Italian Association of Hospital Cardiologists (ANMCO)]Massimo Imazio, Antonio Brucato, Giuseppe Di Tano, et al.
Canadian Journal of Physiology and Pharmacology|February 3, 2022
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axisEdoardo Gronda, Gary D Lopaschuk, Arduino Arduini, et al.
Eating and Weight Disorders : EWD|January 3, 2024
ANMCO (Italian Association of Hospital Cardiologists) scientific statement: obesity in adults-an approach for cardiologistsStefania Angela Di Fusco, Edoardo Mocini, Michele Massimo Gulizia, et al.
Giornale Italiano Di Cardiologia (2006)|October 27, 2022
[The mechanisms mediating the favorable effects of sodium-glucose cotransporter 2 inhibitors on cardiorenal function]Edoardo Gronda, Massimo Iacoviello, Manuela Benvenuto, et al.
Giornale Italiano Di Cardiologia (2006)|March 30, 2021
[Sodium-glucose co-transporter 2 inhibitors: mechanisms of renal action. Implications for diabetes and heart failure]Edoardo Gronda, Massimo Iacoviello, Pasquale Caldarola, et al.
Pageof 29

Showing results (21-30 of 288) with videos related to

Sort By:
Pageof 29
Giornale Italiano Di Cardiologia (2006)|February 28, 2023
[Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease]Manuela Benvenuto, Gaetano Panzarella, Ermal Shehaj, et al.
Frontiers in Cardiovascular Medicine|September 18, 2025
Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)Giovanna Geraci, Carmine Riccio, Fabrizio Oliva, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|August 30, 2021
ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetesEdoardo Gronda, Claudio Napoli, Massimo Iacoviello, et al.
Giornale Italiano Di Cardiologia (2006)|December 27, 2022
[ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure]Stefania Angela Di Fusco, Antonella Spinelli, Stefano Aquilani, et al.
Giornale Italiano Di Cardiologia (2006)|November 27, 2023
[ANMCO Scientific statement: Differences and similarities between direct oral anticoagulants - 10 years of scientific evidence and clinical practice]Stefania Angela Di Fusco, Pietro Scicchitano, Massimo Grimaldi, et al.
Giornale Italiano Di Cardiologia (2006)|June 19, 2018
[Decision-making issues in the clinical management of pericarditis. A statement of the Italian Association of Hospital Cardiologists (ANMCO)]Massimo Imazio, Antonio Brucato, Giuseppe Di Tano, et al.
Canadian Journal of Physiology and Pharmacology|February 3, 2022
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axisEdoardo Gronda, Gary D Lopaschuk, Arduino Arduini, et al.
Eating and Weight Disorders : EWD|January 3, 2024
ANMCO (Italian Association of Hospital Cardiologists) scientific statement: obesity in adults-an approach for cardiologistsStefania Angela Di Fusco, Edoardo Mocini, Michele Massimo Gulizia, et al.
Giornale Italiano Di Cardiologia (2006)|October 27, 2022
[The mechanisms mediating the favorable effects of sodium-glucose cotransporter 2 inhibitors on cardiorenal function]Edoardo Gronda, Massimo Iacoviello, Manuela Benvenuto, et al.
Giornale Italiano Di Cardiologia (2006)|March 30, 2021
[Sodium-glucose co-transporter 2 inhibitors: mechanisms of renal action. Implications for diabetes and heart failure]Edoardo Gronda, Massimo Iacoviello, Pasquale Caldarola, et al.
Pageof 29